Benefits of Insulin Aspart vs Phosphate-Buffered Human Regular Insulin in Persons With Type 1 Diabetes Treated by Means of an Insulin Pump

Abstract

Insulin analog aspart appears to be more effective for continuous subcutaneous insulin infusion than regular human insulin.

Benefits of Three-Month Continuous Glucose Monitoring for Persons With Diabetes Using Insulin Pumps and Sensors

“…Insulin pumps lead not only to the improved glycemic profiles but in comparison with conventional medications, also limit the degree of hypoglycemia 23 . In our recent study we concluded that for this form of treatment, it is better to give priority to short duration insulin analogues (such as insulin aspart, Novorapid) than human insulin Actrapid 25 . This discovery is in accordance with other investigations which have confirmed the superior efficacy of the Lispro insulin analog in external pumps (Humalog) 26 .…”

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience

“…Three studies have compared insulin aspart CSII with buffered RHI CSII, using change in HbA 1c as the outcome [ 120 – 122 ] (Table 3 b). Randomized trials of 7 weeks in 29 adults with T1D [ 120 ] and 16 weeks in 146 adults with T1D [ 121 ] demonstrated little change in HbA 1c from baseline and no between-treatment differences.…”

“…Randomized trials of 7 weeks in 29 adults with T1D [ 120 ] and 16 weeks in 146 adults with T1D [ 121 ] demonstrated little change in HbA 1c from baseline and no between-treatment differences. In contrast, a 90-week study of 21 adults with T1D demonstrated an improvement in HbA 1c after switching from buffered RHI to treatment with insulin aspart CSII (7.89 % vs 7.53 %, respectively, p < 0.05) [ 122 ].…”

Use of new insulins in children

“…It is now recognised that use of a rapid acting analogue in the pump, rather than regular insulin, or buffered regular insulin, can improve the effectiveness of insulin therapy. [75][76][77][78] The concern has been that use of a rapid acting analogue would result in a rapid onset of diabetic ketoacidosis in the event of pump failure. However, a paediatric trial looking at this issue did not demonstrate an increase in diabetic ketoacidosis when insulin Lispro was used in place of regular insulin.…”